Document Detail

Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
MedLine Citation:
PMID:  16716479     Owner:  NLM     Status:  MEDLINE    
Major depressive disorder (MDD) is blaimed to play a role in the onset of coronary artery disease (CAD). The aim of the present study was to investigate serum paraoxonase/arylesterase activities and oxidation of apolipoprotein B-containing lipoproteins in patients with MDD. Oxidation of lipoproteins plays an important role in atherogenesis and the enzyme paraoxonase, has been shown to prevent lipoprotein oxidation. Furthermore, low paraoxonase activity was suggested to predict CAD. Eighty-six patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for MDD and 36 healthy control subjects were included in the study. Serum paraoxonase and arylesterase activities were determined spectrophotometrically. Malondialdehyde (MDA) levels of apolipoprotein B-containing lipoproteins were determined before (basal) and after incubation with copper-sulphate, that yielded basal- and Delta-MDA values, respectively. Serum paraoxonase/arylesterase activities were significantly reduced in the post-treatment group compared with the pre-treatment group. Basal-MDA (MDA) level was significantly higher in the MDD group compared with the control group. Delta-MDA level of the severe MDD group was significantly higher than that of the control group. There was a positive correlation between the oxidizability of apolipoprotein B-containing lipoproteins and the severity of the disease. Total cholesterol, HDL-cholesterol, LDL-cholesterol, apolipoprotein B levels were significantly higher and apolipoprotein AI levels were significantly lower in the MDD group compared with those of the control group. The findings of the present study suggest that: 1) antidepressant treatment might reduce serum paraoxonase activity/mass; 2) oxidation and oxidizability of apolipoprotein B-containing lipoproteins seem to be increased in MDD.
Asli Sarandol; Emre Sarandol; Salih Saygin Eker; Esra Ugurlu Karaagac; Banu Zafer Hizli; Melahat Dirican; Selcuk Kirli
Related Documents :
10408999 - Compliance with fluvastatin treatment characterization of the noncompliant population w...
19184689 - Improving the health of diabetic patients through resident-initiated group visits.
21495839 - The effect of chronic sputum production on respiratory symptoms in severe copd.
8857479 - Effects of short-term reduction in serum cholesterol with simvastatin in patients with ...
11793629 - A comparison of clinical outcome studies among cholesterol-lowering agents.
2677429 - Prolonged zidovudine therapy in patients with aids and advanced aids-related complex. a...
17913759 - Prevalence and symptomatology of depression in older people living in institutions in e...
1616359 - Double blind, placebo controlled study of metronidazole as a disease modifying agent in...
7116069 - Pain and depression.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-05-23
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  30     ISSN:  0278-5846     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-03     Completed Date:  2006-08-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  1103-8     Citation Subset:  IM    
Department of Psychiatry, Uludag University Medical Faculty, 16059 Bursa, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antidepressive Agents / adverse effects,  therapeutic use
Apolipoproteins B / blood*
Aryldialkylphosphatase / blood*
C-Reactive Protein / metabolism
Carboxylic Ester Hydrolases / blood*
Cholesterol / blood
Cholesterol, HDL / blood
Depressive Disorder, Major / drug therapy,  metabolism*
Homocysteine / blood
Lipoproteins / blood*
Malondialdehyde / blood
Middle Aged
Psychiatric Status Rating Scales
Triglycerides / blood
Reg. No./Substance:
0/Antidepressive Agents; 0/Apolipoproteins B; 0/Cholesterol, HDL; 0/Lipoproteins; 0/Triglycerides; 454-28-4/Homocysteine; 542-78-9/Malondialdehyde; 57-88-5/Cholesterol; 9007-41-4/C-Reactive Protein; EC 3.1.1.-/Carboxylic Ester Hydrolases; EC; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  How does social comparison within a self-help group influence adjustment to chronic illness? A longi...
Next Document:  Human erythrocytes are affected in vitro by extracts of Ugni molinae leaves.